Navigation Links
Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
Date:11/3/2009

FRANKLIN LAKES, N.J., Nov. 3 /PRNewswire-FirstCall/ --

Third-Quarter 2009 Highlights:

  • Record GAAP diluted EPS of $0.69, up 19.0 percent from $0.58 in third-quarter 2008
  • Record diluted EPS, excluding $0.06 in amortization of intangible assets from the 2003 spin-off, of $0.75, up 19.0 percent from $0.63 in third-quarter 2008
  • Total net revenues increased 17.8 percent to $14.8 billion
  • Specialty pharmacy revenues increased 19.2 percent to a record of over $2.4 billion
  • Generic dispensing rate increased 3.3 percentage points to a record 67.7 percent
  • EBITDA per adjusted prescription increased to a record $3.27 from $3.19 in third-quarter 2008
  • Cash balance at quarter-end of $2.0 billion, after paying down $400 million of short-term debt

September Year-to-Date 2009 Highlights:

  • Record adjusted prescription volume of over 671 million, up 12.3 percent over 2008
  • Record EBITDA of $2.06 billion, a 12.2 percent increase over 2008
  • Cash flows from operations reached a record $2.5 billion, a three-fold increase over 2008

2009 Guidance Raised and Narrowed:

  • Full-year 2009 GAAP diluted EPS guidance again raised and narrowed from previous guidance to a range of $2.58 to $2.60, now representing 21 to 22 percent growth over 2008.
  • Full-year 2009 diluted EPS, excluding amortization of intangible assets, raised and narrowed to a range of $2.80 to $2.82, now representing 20 to 21 percent growth over 2008.

2010 Guidance:

  • Full-year 2010 GAAP diluted EPS guidance of $3.05 to $3.15, representing growth of 17 to 22 percent over revised 2009 guidance. Full-year 2010 diluted EPS excluding amortization of intangible assets, of $3.28 to $3.38, representing growth of 16 to 21 percent over revised 2009 guidance.

Medco Health Solutions, Inc. (NYSE: '/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Medco to Present at November 2009 Investor Conferences
2. The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need
3. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
4. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
5. Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children
6. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
9. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
10. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2